.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #210
Personalizing ADT Across the Prostate Cancer Spectrum
with Dr. Rana McKay
What is the role of androgen deprivation therapy (ADT) in prostate cancer treatment? In this episode of the BackTable Urology Podcast, Dr. Rana McKay, a medical oncologist from UC San Diego, joins host Dr. Aditya Bagrodia to discuss the administration of ADT and other management strategies for prostate cancer.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2025, January 21). Ep. 210 – Personalizing ADT Across the Prostate Cancer Spectrum [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Dr. Rana McKay
Dr. Rana McKay is a medical oncologist and associate professor at UC San Diego Health in California.
Dr. Aditya Bagrodia
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Synopsis
The doctors offer a historical perspective into the evolution of ADT over time and discuss the variety of different ADT treatment options available. They compare management strategies for localized and metastatic prostate cancer and discuss how to align therapy with patient goals, focusing on the side effects. The conversation also explores the impact of prostate-specific membrane antigen (PSMA) PET imaging on management and the future directions of hormonal therapies in urologic oncology.
Timestamps
00:00 - Introduction
05:25 - ADT Options
10:36 - Choosing an Agent and Managing Side Effects
26:42 - Continuous Versus Intermittent Therapy
30:30 - Closing Remarks
Resources
Photocure
https://www.photocure.com/
Transcript Preview
[Dr. Rana McKay]
What we've seen with the GnRH antagonists is that there does seem to be a little bit faster time to T-recovery post-discontinuation of the treatment. I think there's very controversial data about the potential cardiovascular risk mitigation with antagonists versus agonists. I think there's a choice in the matter. Some patients may have a strong preference one way or another, and in which case they do, there's options, which is a good thing.
Some patients are very fearful of side effects, to the point where you may not necessarily want to give them a six-month injection. The way to actually help encourage that they get evidence-based treatment is by saying, ‘you know what, let's just do one month at a time, or let's just do the pills’. Then if you have any side effects, we'll just stop. I think that can be very appealing to some individuals.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
ADT Side Effects: Balancing Efficacy & Complications
How Testosterone Levels Inform Intermittent Androgen Deprivation Therapy (ADT)
Personalizing ADT: A Modern Approach to High Risk Prostate Cancers
Topics
